Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

KEYNOTE-361 Investigators

43 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie